{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:06:23Z","timestamp":1790208383316,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.nmd.2014.06.432","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T12:32:18Z","timestamp":1403267538000},"page":"943-952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications"],"prefix":"10.1016","volume":"24","author":[{"given":"Ellen M.","family":"Moran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2014.06.432_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","article-title":"Pathogenesis and therapies of immune-mediated myopathies","volume":"11","author":"Dalakas","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2014.06.432_b0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","article-title":"Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/BOR.0b013e3282efe261","article-title":"A gene expression approach to study perturbed pathways in myositis","volume":"19","author":"Greenberg","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrrheum.2011.39","article-title":"Pathogenesis, classification and treatment of inflammatory myopathies","volume":"7","author":"Zong","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2796.2010.02334.x","article-title":"Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?","volume":"269","author":"Loell","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","article-title":"The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis","volume":"48","author":"Kissel","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.410190203","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury","volume":"19","author":"Arahata","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0045","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ana.410230511","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+ cytotoxic and T8+ suppressor cells","volume":"23","author":"Arahata","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0050","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1172\/JCI118749","article-title":"Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis","volume":"97","author":"Goebels","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2014.06.432_b0055","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","article-title":"T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells","volume":"183","author":"Fasth","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0060","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/NEN.0b013e31826183c8","article-title":"Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis","volume":"71","author":"Askanas","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0065","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.06.432_b0070","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preusse","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2014.06.432_b0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.410230210","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis","volume":"23","author":"Arahata","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0080","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.4049\/jimmunol.161.11.5943","article-title":"Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions","volume":"161","author":"Behrens","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","article-title":"Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies","volume":"155","author":"Murata","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2014.06.432_b0090","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/brain\/awg114","article-title":"Muscle fibres and cultured muscle cells express the B7.1\/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies","volume":"126","author":"Wiendl","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2014.06.432_b0095","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/brain\/awh148","article-title":"Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity","volume":"127","author":"Schmidt","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2014.06.432_b0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.149.2.661","article-title":"Human myoblasts as antigen-presenting cells","volume":"149","author":"Goebels","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0165-5728(03)00093-6","article-title":"Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies","volume":"138","author":"Wiendl","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","article-title":"Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle","volume":"94","author":"De Visser","year":"1989","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2014.06.432_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2012-201822","article-title":"Whole microvascular unit deletions in dermatomyositis","volume":"72","author":"Gitiaux","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2014.06.432_b0125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2014.06.432_b0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0140","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.10140","volume":"46","author":"Englund","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0145","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2014.06.432_b0155","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0160","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.06.432_b0165","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/304177a0","article-title":"Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity","volume":"304","author":"Mathews","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2014.06.432_b0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/PL00007850","article-title":"Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies","volume":"249","author":"Hengstman","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0185","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00415-005-0683-5","article-title":"High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders","volume":"252","author":"Hengstman","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2014.06.432_b0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.nmd.2014.06.432_b0195","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between Mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0200","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","article-title":"Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis","volume":"7","author":"Robinson","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0205","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0210","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0215","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0220","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","article-title":"Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle","volume":"60","author":"Mammen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0225","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrrheum.2013.26","article-title":"A critical role for immature muscle precursors in myositis","volume":"9","author":"Tournadre","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0230","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mus.10462","article-title":"Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies","volume":"28","author":"Figarella-Branger","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2014.06.432_b0240","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","article-title":"Differential expression of chemokines in inflammatory myopathies","volume":"58","author":"De Bleecker","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.06.432_b0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00218-2","article-title":"Expression of IFN-gamma-inducible chemokines in inclusion body myositis","volume":"141","author":"Raju","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.12194","article-title":"Diagnosis, pathogenesis and treatment of myositis: recent advances","volume":"175","author":"Carstens","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0255","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2005.05.003","article-title":"Immunobiology of muscle: advances in understanding an immunological microenvironment","volume":"26","author":"Wiendl","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0260","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/BOR.0b013e32834b41d2","article-title":"An update on pathogenic mechanisms of inflammatory myopathies","volume":"23","author":"Rayavarapu","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0265","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1212\/WNL.57.5.755","article-title":"DNA microarray gene expression analysis technology and its application to neurological disorders","volume":"57","author":"Greenberg","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.06.432_b0270","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2014.06.432_b0275","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1\u22170501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0280","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","article-title":"Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies","volume":"54","author":"Choi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.06.432_b0285","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0290","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2133.2005.06786.x","article-title":"Evidence for a role of type I interferons in the pathogenesis of dermatomyositis","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0295","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","article-title":"Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers","volume":"179","author":"Ivanidze","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2014.06.432_b0300","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm.3268","article-title":"How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases","volume":"19","author":"Baeten","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0305","doi-asserted-by":"crossref","first-page":"e24048","DOI":"10.1371\/journal.pone.0024048","article-title":"IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates","volume":"6","author":"Moran","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2014.06.432_b0310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrrheum.2012.205","article-title":"The role of IL-17-secreting mast cells in inflammatory joint disease","volume":"9","author":"Kenna","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0315","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/art.22733","article-title":"Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified","volume":"56","author":"Miossec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0320","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/art.10816","article-title":"Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy","volume":"48","author":"Miossec","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0325","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0330","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0335","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2014.06.432_b0340","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.162.3.1246","article-title":"IL-17 is produced by some proinflammatory Th1\/Th0 cells but not by Th2 cells","volume":"162","author":"Aarvak","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/cyto.2000.0811","article-title":"Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions","volume":"13","author":"Chabaud","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.nmd.2014.06.432_b0350","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4049\/jimmunol.165.11.6107","article-title":"Microbial lipopeptides induce the production of IL-17 in Th cells","volume":"165","author":"Infante-Duarte","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0355","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2014.06.432_b0360","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.4049\/jimmunol.170.9.4432","article-title":"Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection","volume":"170","author":"Happel","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0365","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0370","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0375","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0380","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0390","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"IL-17+CD8+ T-cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0395","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/eji.200939412","article-title":"A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity","volume":"39","author":"Huber","year":"2009","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.nmd.2014.06.432_b0400","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.4049\/jimmunol.1302190","article-title":"Pharmacologic inhibition of RORgammat regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo","volume":"192","author":"Skepner","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0405","doi-asserted-by":"crossref","first-page":"607073","DOI":"10.1155\/2013\/607073","article-title":"T helper 17 cells in autoimmune liver diseases","volume":"2013","author":"Abe","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0410","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1189\/jlb.1213633","article-title":"Th17 cells and Tregs: unlikely allies","volume":"95","author":"Chen","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.nmd.2014.06.432_b0415","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/art.30582","article-title":"Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement","volume":"63","author":"Moran","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0420","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar2772","article-title":"Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies","volume":"11","author":"Moran","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2014.06.432_b0425","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/cmi.2010.21","article-title":"Interleukin-17 and its expanding biological functions","volume":"7","author":"Xu","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0430","first-page":"76","article-title":"Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease","volume":"11","author":"Mountz","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0435","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/art.38059","article-title":"Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice","volume":"65","author":"Wang","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0440","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.4049\/jimmunol.0903133","article-title":"IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16","volume":"184","author":"Xie","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0445","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ni.1741","article-title":"Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus","volume":"10","author":"Doreau","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0450","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2009.08.025","article-title":"Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis","volume":"31","author":"Lin","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.nmd.2014.06.432_b0455","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00032-8","article-title":"Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis","volume":"137","author":"Chevrel","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0465","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/art.11428","article-title":"Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells","volume":"50","author":"Page","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0470","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","article-title":"Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins","volume":"46","author":"Tournadre","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.nmd.2014.06.432_b0475","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-009-1316-7","article-title":"Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis","volume":"29","author":"Kim","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0480","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/NEN.0b013e31826bf7f3","article-title":"Toll-like receptors promote inflammation in idiopathic inflammatory myopathies","volume":"71","author":"Brunn","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2014.06.432_b0485","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/keu005","article-title":"Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2014.06.432_b0490","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2014.06.432_b0495","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/rheumatology\/keq151","article-title":"Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand","volume":"49","author":"Szodoray","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2014.06.432_b0500","unstructured":"Hatice Bilgic SRY, McNallan Kelly T, Wilson Joseph C, Koeuth T, Bauer Jason W, Moder Kevin G, Amin Shreyasee, Michet Clement J, Peterson Erik J, Baechler Emily C, Reed Ann M. Abstract # 2053 IL-17 and IFN-regulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. In: American College of Rheumatology (ACR). San Francisco; 2008."},{"key":"10.1016\/j.nmd.2014.06.432_b0505","doi-asserted-by":"crossref","first-page":"S877","DOI":"10.1002\/art.37754","article-title":"Cell depletion in refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) \u2013 the RIM (rituximab in myositis) trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0510","first-page":"S887","article-title":"Interferon-regulated chemokine and innate cytokine scores identify refractory myositis patients that respond better to rituximab therapy","volume":"65","author":"Lopez de Padilla","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0515","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","article-title":"Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis","volume":"40","author":"Shen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.nmd.2014.06.432_b0520","doi-asserted-by":"crossref","first-page":"e88788","DOI":"10.1371\/journal.pone.0088788","article-title":"Th1 response and systemic Treg deficiency in inclusion body myositis","volume":"9","author":"Allenbach","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2014.06.432_b0525","doi-asserted-by":"crossref","first-page":"345347","DOI":"10.1155\/2013\/345347","article-title":"Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0530","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2004.032359","article-title":"Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors","volume":"64","author":"Chevrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2014.06.432_b0535","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bbamcr.2012.01.001","article-title":"Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2","volume":"1823","author":"Kocic","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2014.06.432_b0540","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.biocel.2012.11.010","article-title":"Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase","volume":"45","author":"Kocic","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.nmd.2014.06.432_b0545","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2014.06.432_b0550","first-page":"S877","article-title":"Biomarker and serologic predictors of clinical improvement after B Cell depletion in refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) \u2013 the RIM (rituximab in myositis) trial","volume":"65","author":"Reed","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0555","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0560","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2014.06.432_b0565","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","article-title":"Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2014.06.432_b0570","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0575","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneuroim.2010.03.013","article-title":"FOXP3+ T regulatory cells in idiopathic inflammatory myopathies","volume":"225","author":"Waschbisch","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0580","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaut.2010.07.006","article-title":"Characterization of regulatory T cells in patients with dermatomyositis","volume":"35","author":"Antiga","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2014.06.432_b0585","first-page":"732","article-title":"P5.27 evidence for the implication of Th-1 and Treg cells but not Th-17 in sporadic inclusion body myositis","volume":"21","author":"Allenbach","year":"2011","journal-title":"NMD"},{"key":"10.1016\/j.nmd.2014.06.432_b0590","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2013.00245","article-title":"Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases","volume":"4","author":"Keijzer","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0595","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2014.06.432_b0600","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/ket279","article-title":"Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy","volume":"53","author":"Venalis","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2014.06.432_b0605","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0610","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2014.06.432_b0615","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","article-title":"Elevated serum levels of interleukin-1 receptor antagonist in polymyositis\/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response","volume":"37","author":"Gabay","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2014.06.432_b0620","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.nmd.2014.06.432_b0625","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2014.06.432_b0630","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/eji.201242740","article-title":"Small molecule inhibitors of RORgammat: targeting Th17 cells and other applications","volume":"42","author":"Huh","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nmd.2014.06.432_b0635","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/nm0913-1078a","article-title":"Flurry of deal-making surrounds new autoimmunity target","volume":"19","author":"Williams","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2014.06.432_b0640","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4152","article-title":"IL-17 antibodies gain momentum","volume":"12","author":"Tse","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614005835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614005835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:02:54Z","timestamp":1760774574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896614005835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0960896614005835"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2014.06.432","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2014.06.432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}